Arcturus Therapeutics (NASDAQ:ARCT) Trading Down 6.1%

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)’s stock price fell 6.1% during mid-day trading on Thursday . The company traded as low as $26.10 and last traded at $26.21. 435,006 shares changed hands during mid-day trading, a decline of 5% from the average session volume of 457,692 shares. The stock had previously closed at $27.91.

Analysts Set New Price Targets

Several equities research analysts have issued reports on the stock. Citigroup raised their price target on shares of Arcturus Therapeutics from $40.00 to $48.00 and gave the stock a “buy” rating in a research note on Thursday, February 8th. William Blair restated an “outperform” rating on shares of Arcturus Therapeutics in a research report on Friday, March 8th. Finally, HC Wainwright reissued a “buy” rating and set a $60.00 price target on shares of Arcturus Therapeutics in a research note on Wednesday, March 20th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $61.33.

Arcturus Therapeutics Price Performance

The business’s fifty day moving average is $33.16 and its 200-day moving average is $29.90.

Arcturus Therapeutics (NASDAQ:ARCT) last announced its quarterly earnings results on Thursday, March 7th. The biotechnology company reported ($0.32) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.69) by $1.37. The company had revenue of $33.99 million for the quarter, compared to analyst estimates of $64.14 million. Arcturus Therapeutics had a negative net margin of 15.65% and a negative return on equity of 18.22%. As a group, equities analysts anticipate that Arcturus Therapeutics Holdings Inc. will post -2.83 EPS for the current year.

Insider Buying and Selling at Arcturus Therapeutics

In other news, COO Pad Chivukula sold 17,435 shares of the business’s stock in a transaction dated Monday, March 25th. The stock was sold at an average price of $35.02, for a total transaction of $610,573.70. Following the completion of the sale, the chief operating officer now owns 473,448 shares in the company, valued at approximately $16,580,148.96. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 13.80% of the stock is owned by company insiders.

Hedge Funds Weigh In On Arcturus Therapeutics

A number of hedge funds have recently made changes to their positions in ARCT. AJOVista LLC acquired a new position in Arcturus Therapeutics during the 4th quarter worth approximately $65,000. New York State Teachers Retirement System purchased a new stake in shares of Arcturus Therapeutics during the third quarter valued at approximately $53,000. Quest Partners LLC acquired a new position in shares of Arcturus Therapeutics during the fourth quarter worth $67,000. Public Employees Retirement System of Ohio purchased a new position in shares of Arcturus Therapeutics in the fourth quarter valued at $89,000. Finally, China Universal Asset Management Co. Ltd. grew its holdings in Arcturus Therapeutics by 352.3% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 3,089 shares of the biotechnology company’s stock valued at $97,000 after purchasing an additional 2,406 shares in the last quarter. Hedge funds and other institutional investors own 94.54% of the company’s stock.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.